Abeona Therapeutics (ABEO) director receives 37,313-share restricted stock grant

Rhea-AI Filing Summary

Abeona Therapeutics Inc. director Bernhardt G. Zeiher received a grant of 37,313 shares of common stock on January 26, 2026. The shares were awarded at a price of $0.00 per share as restricted stock. After this grant, he directly holds 84,458 shares. All of the restricted stock will vest on January 26, 2027, meaning the award becomes fully owned on that date if conditions are met.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeiher Bernhardt G

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		37,313(1)	A	$0.00	84,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All of the restricted stock will vest on January 26, 2027.

	/s/ Bernhardt Zeiher	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for director Bernhardt Zeiher?

Abeona Therapeutics reported that director Bernhardt G. Zeiher received 37,313 shares of common stock as a restricted stock grant. The award was dated January 26, 2026 at a price of $0.00 per share and increased his direct holdings to 84,458 shares.

How many Abeona Therapeutics (ABEO) shares does Bernhardt Zeiher hold after this Form 4 transaction?

After the reported grant, Bernhardt G. Zeiher directly owns 84,458 shares of Abeona Therapeutics common stock. This reflects the addition of 37,313 restricted shares awarded on January 26, 2026, as disclosed in the Form 4 insider filing with the SEC.

What is the vesting schedule for Bernhardt Zeiher’s restricted stock in Abeona Therapeutics (ABEO)?

All of Bernhardt G. Zeiher’s 37,313 restricted shares will vest on January 26, 2027. Vesting means the restrictions on the stock lapse at that time, and he fully owns the shares if any service or other conditions have been satisfied.

Was there any cash paid for the Abeona Therapeutics (ABEO) shares granted to director Bernhardt Zeiher?

No cash was paid for this award; the 37,313 shares of Abeona Therapeutics common stock were granted at a price of $0.00 per share. This indicates a compensatory equity grant rather than an open-market purchase by the director.

What does this Abeona Therapeutics (ABEO) Form 4 filing indicate about insider ownership?

The Form 4 shows director Bernhardt G. Zeiher receiving a 37,313-share restricted stock grant, bringing his direct holdings to 84,458 shares. It documents equity-based compensation and provides transparency into changes in insider ownership at Abeona Therapeutics.

Who is the reporting person in the Abeona Therapeutics (ABEO) Form 4 filed on January 27, 2026?

The reporting person is Bernhardt G. Zeiher, identified as a director of Abeona Therapeutics Inc. The Form 4 reports his acquisition of 37,313 restricted shares of common stock and his total direct ownership of 84,458 shares following the transaction.